Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-1 for early Parkinson's disease (low-dose vs high-dose)
ChiCTR2100042537Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of monosialotetrahexosylganglioside in Parkinson's disease (PD) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Motor symptom scores, Non-motor symptom scores and 1 more. Started Mar 2021; status: recruiting.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR2100042537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042537.